EnPlusOne Biosciences Appoints Clare Murray, Ph.D., as CEO
Company - People | Apr 17, 2025 | Breakout Ventures Associates L
EnPlusOne Biosciences, a biotechnology company focused on enzyme-driven RNA synthesis, has announced the appointment of Clare Murray, Ph.D., as its new CEO. Dr. Murray brings extensive experience in corporate strategy and business development in the biotech sector. She has previously led significant transactions with global pharmaceutical and biotech firms, making her an ideal candidate to guide EnPlusOne's growth and commercialization efforts. The company is at a pivotal point in its development, with its innovative ezRNA platform set to address key challenges in RNA therapeutic manufacturing. EnPlusOne's focus on sustainable, scalable RNA synthesis positions it as a promising leader in the industry, particularly as demand for high-quality RNA surges. The appointment coincides with a recent $10 million financing round co-led by Northpond Ventures and Breakout Ventures. Dr. Murray's leadership is expected to propel EnPlusOne's strategic initiatives and commercial expansion.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – EnPlusOne Biosciences is based in Watertown, Massachusetts, and the strategic collaborations and investment activities are primarily discussed within the context of the U.S. market.
Industry
- Biotechnology – The article focuses on EnPlusOne Biosciences, a biotechnology company developing RNA synthesis technologies, which is a subset of the broader Biotechnology industry.
- Pharmaceuticals – Clare Murray has experience leading transactions with global pharmaceutical companies, indicating the article's relevance to the Pharmaceuticals industry.
Financials
- $10 million – The amount raised in a recent financing round co-led by Northpond Ventures and Breakout Ventures for EnPlusOne Biosciences.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EnPlusOne Biosciences | Target company | Company | A biotechnology company focused on revolutionizing RNA therapeutics through enzymatic synthesis. |
| Clare Murray, Ph.D. | Chief Executive Officer | Person | Appointed CEO of EnPlusOne Biosciences, she has extensive experience in corporate strategy and biotech business development. |
| Breakout Ventures | Investor | Company | Private equity firm involved in the $10 million financing round for EnPlusOne Biosciences. |
| Northpond Ventures | Investor | Company | Venture capital firm that co-led a $10 million financing round for EnPlusOne Biosciences. |
| Steven Kasok | Chair of the EnPlusOne Board of Directors | Person | Chairman of the Board at EnPlusOne Biosciences. |
| Paxton Major | Managing Director | Person | Managing Director at Northpond Ventures. |
| Dan Ahlstedt | Co-founder and COO | Person | Co-founder and Chief Operating Officer of EnPlusOne Biosciences. |